查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1595632

前列腺保健市場：按疾病類型、治療類型、藥物治療類型分類 - 全球預測 2025-2030

Prostate Health Market by Disease Type (Benign Prostatic Hyperplasia, Prostate Cancer, Prostatitis), Therapy Type (AR-Directed Therapies, Cytotoxic Agents, Hormone ADT), Drug Treatment Type - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

攝護腺健康市場2023年估值為521.3億美元，預計到2024年將達到574.8億美元，複合年成長率為10.74%，到2030年將達到1064.9億美元。

攝護腺健康市場包括旨在維持和改善攝護腺健康的產品、服務和治療。這包括針對良性前列腺增生 (BPH)、前列腺炎和前列腺癌等疾病的藥物、外科手術、診斷、營養食品和醫療設備。由於人口老化和生活方式因素，前列腺相關疾病的盛行率不斷上升，支持了對該市場的需求。治療應用範圍從預防保健到高級治療方法，最終用途包括醫院、專科診所、研究機構和患者自我護理。主要的市場促進因素包括診斷和治療方法的技術進步、意識的提高以及醫療保健支出的增加。然而，高昂的治療費用、藥物和治療的副作用以及保險範圍問題等限制因素給市場擴張帶來了挑戰。潛在的商機在於個人化醫療、用於遠距患者管理的遠端醫療以及微創手術的創新，這些創新越來越受到關注。公司可以透過投資研發、建立策略夥伴關係以及利用數位平台來加強患者教育和參與來利用這些優勢。然而，新藥認證的監管限制以及多方爭奪市場佔有率的競爭格局等挑戰尤其需要謹慎處理。創新可能會致力於開發更有效、侵入性更小的診斷工具，並促進生技藥品和基因療法的突破，從而有可能改變治療模式。此外，促進學術機構和生物技術公司之間的合作可以刺激研究並促進從實驗室到臨床的轉變。在技​​術不斷進步以及患者和醫療保健提供者偏好不斷變化的推動下，市場的動態本質要求策略制定具有敏捷性和遠見。因此，公司應該關注適應性經營模式，確保靈活性和對新趨勢和消費者需求的應對力。

主要市場統計
基準年[2023] 521.3億美元
預測年份 [2024] 574.8億美元
預測年份 [2030] 1064.9億美元
複合年成長率（%） 10.74%

市場動態：揭示快速發展的前列腺健康市場的關鍵市場洞察

供需的動態交互作用正在改變前列腺健康市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時也能幫助企業了解消費行為及其對製造業的影響。

  • 市場促進因素
    • 人口老化加劇以及良性前列腺增生和前列腺癌盛行率增加
    • 政府加大舉措推動診斷技術
    • 荷爾蒙療法的技術創新以及基因組學和蛋白​​質組學的進步
  • 市場限制因素
    • 與良性攝護腺增生藥物相關的副作用
  • 市場機會
    • 增加研究導致開發新藥，如 rucaparib 和 olaparib
    • 開發前列腺癌新治療方法
  • 市場挑戰
    • 對攝護腺健康缺乏認知

波特五力：駕馭攝護腺健康市場的策略工具

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解攝護腺健康市場的外部影響

外部宏觀環境因素在塑造前列腺健康市場的表現動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析 了解攝護腺健康市場的競爭格局

對前列腺健康市場的詳細市場佔有率分析可以對供應商績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來發現自己的競爭定位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣攝護腺健康市場供應商的績效評估

FPNV定位矩陣是評估攝護腺健康市場供應商的重要工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。這四個象限使您能夠清晰、準確地分類供應商，以確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析和建議繪製前列腺健康市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，對前列腺健康市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機，並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：對當前市場環境的詳細審查、主要企業的廣泛資料、對其在市場中的影響力和整體影響力的評估。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：全面分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監管核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點關注可望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 人口老化加劇，良性前列腺增生和前列腺癌發生率增加
      • 擴大政府努力改善診斷技術
      • 荷爾蒙療法藥物創新以及基因組學和蛋白​​質組學開發
    • 抑制因素
      • 與 BPH 治療藥物相關的副作用
    • 機會
      • 增加研究導致開發新藥，如 rucaparib 和 olaparib
      • 開發前列腺癌新治療方法
    • 任務
      • 攝護腺健康意識淡薄
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章前列腺保健市場：依疾病類型

  • 良性攝護腺增生
  • 攝護腺癌
  • 攝護腺炎

第7章前列腺保健市場治療類型

  • AR導向療法
  • 細胞毒性藥物
  • 荷爾蒙ADT
  • 聚（ADP-核糖）聚合酵素（PARP）抑制劑

第8章按藥物治療類型分類的前列腺保健市場

  • 5-α還原酶抑制劑
    • 度他雄胺
    • Finasteride
  • α阻斷劑
    • 阿夫唑嗪
    • 多沙唑嗪
    • 西洛多辛
    • Tamsulosin

第9章美洲前列腺保健市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章亞太地區前列腺保健市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章歐洲、中東和非洲前列腺保健市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Elekta AB
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • Ferring Pharmaceuticals Inc.
  • GlaxoSmithKline PLC
  • Ipsen Limited
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi SA
  • Takeda Pharmaceutical Company Ltd.
Product Code: MRR-8201ABF20E0C

The Prostate Health Market was valued at USD 52.13 billion in 2023, expected to reach USD 57.48 billion in 2024, and is projected to grow at a CAGR of 10.74%, to USD 106.49 billion by 2030.

The prostate health market encompasses products, services, and treatments aimed at maintaining or improving the health of the prostate gland. This includes pharmaceuticals, surgical procedures, diagnostics, dietary supplements, and medical devices targeting conditions such as benign prostatic hyperplasia (BPH), prostatitis, and prostate cancer. The necessity of this market is underscored by the increasing prevalence of prostate-related disorders, fueled by aging populations and lifestyle factors. Applications span from preventive healthcare to advanced treatment methods, with end-use encompassing hospitals, specialty clinics, research institutes, and patient self-care. Key market growth drivers include technological advancements in diagnostics and treatment modalities, increasing awareness, and heightened healthcare expenditure. However, limitations such as high treatment costs, side effects of medications and procedures, and insurance coverage issues challenge market expansion. Potential opportunities lie in personalized medicine, telemedicine for remote patient management, and innovations in minimally invasive procedures, which are increasingly gaining traction. Businesses can capitalize on these by investing in R&D, forming strategic partnerships, and leveraging digital platforms for enhanced patient education and engagement. Nonetheless, challenges such as regulatory constraints, particularly on new drug approvals, and the competitive landscape with several players vying for market share, require careful navigation. Innovation could be directed towards developing more effective and less invasive diagnostic tools, and fostering breakthroughs in biologics and gene therapy with the potential to revolutionize treatment paradigms. Furthermore, fostering collaborations between academic institutions and biotech companies can spur research and expedite translation from bench to bedside. The nature of the market is dynamic, driven by constant advancements in technology and shifts in patient and healthcare provider preferences, necessitating agility and foresight in strategy formulation. Companies should thus focus on adaptive business models, ensuring flexibility and responsiveness to emerging trends and consumer needs.

KEY MARKET STATISTICS
Base Year [2023] USD 52.13 billion
Estimated Year [2024] USD 57.48 billion
Forecast Year [2030] USD 106.49 billion
CAGR (%) 10.74%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Prostate Health Market

The Prostate Health Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising aging population and increasing prevalence rate of benign prostatic hyperplasia and prostate cancer
    • Growing government's initiatives for advancement in technology in diagnosis
    • Innovation in hormone therapy drugs and developments genomics and proteomics
  • Market Restraints
    • Side-effects associated with BPH medications
  • Market Opportunities
    • Increasing researches leading to development of new drugs like Rucaparib and Olaparib
    • Development of novel modality of therapy for prostate cancer
  • Market Challenges
    • Low awareness regarding prostate health

Porter's Five Forces: A Strategic Tool for Navigating the Prostate Health Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Prostate Health Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Prostate Health Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Prostate Health Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Prostate Health Market

A detailed market share analysis in the Prostate Health Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Prostate Health Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Prostate Health Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Prostate Health Market

A strategic analysis of the Prostate Health Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Prostate Health Market, highlighting leading vendors and their innovative profiles. These include Astellas Pharma Inc., AstraZeneca PLC, Bayer AG, Bristol-Myers Squibb Company, Elekta AB, Eli Lilly and Company, F. Hoffmann-La Roche AG, Ferring Pharmaceuticals Inc., GlaxoSmithKline PLC, Ipsen Limited, Merck & Co., Inc., Novartis AG, Pfizer Inc., Sanofi S.A., and Takeda Pharmaceutical Company Ltd..

Market Segmentation & Coverage

This research report categorizes the Prostate Health Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Disease Type, market is studied across Benign Prostatic Hyperplasia, Prostate Cancer, and Prostatitis.
  • Based on Therapy Type, market is studied across AR-Directed Therapies, Cytotoxic Agents, Hormone ADT, and Poly (ADP-Ribose) Polymerase (PARP) Inhibitors.
  • Based on Drug Treatment Type, market is studied across 5-Alpha Reductase Inhibitors and Alpha Blockers. The 5-Alpha Reductase Inhibitors is further studied across Dutasteride and Finasteride. The Alpha Blockers is further studied across Alfuzosin, Doxazosin, Silodosin, and Tamsulosin.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising aging population and increasing prevalence rate of benign prostatic hyperplasia and prostate cancer
      • 5.1.1.2. Growing government's initiatives for advancement in technology in diagnosis
      • 5.1.1.3. Innovation in hormone therapy drugs and developments genomics and proteomics
    • 5.1.2. Restraints
      • 5.1.2.1. Side-effects associated with BPH medications
    • 5.1.3. Opportunities
      • 5.1.3.1. Increasing researches leading to development of new drugs like Rucaparib and Olaparib
      • 5.1.3.2. Development of novel modality of therapy for prostate cancer
    • 5.1.4. Challenges
      • 5.1.4.1. Low awareness regarding prostate health
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Prostate Health Market, by Disease Type

  • 6.1. Introduction
  • 6.2. Benign Prostatic Hyperplasia
  • 6.3. Prostate Cancer
  • 6.4. Prostatitis

7. Prostate Health Market, by Therapy Type

  • 7.1. Introduction
  • 7.2. AR-Directed Therapies
  • 7.3. Cytotoxic Agents
  • 7.4. Hormone ADT
  • 7.5. Poly (ADP-Ribose) Polymerase (PARP) Inhibitors

8. Prostate Health Market, by Drug Treatment Type

  • 8.1. Introduction
  • 8.2. 5-Alpha Reductase Inhibitors
    • 8.2.1. Dutasteride
    • 8.2.2. Finasteride
  • 8.3. Alpha Blockers
    • 8.3.1. Alfuzosin
    • 8.3.2. Doxazosin
    • 8.3.3. Silodosin
    • 8.3.4. Tamsulosin

9. Americas Prostate Health Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Prostate Health Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Prostate Health Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Astellas Pharma Inc.
  • 2. AstraZeneca PLC
  • 3. Bayer AG
  • 4. Bristol-Myers Squibb Company
  • 5. Elekta AB
  • 6. Eli Lilly and Company
  • 7. F. Hoffmann-La Roche AG
  • 8. Ferring Pharmaceuticals Inc.
  • 9. GlaxoSmithKline PLC
  • 10. Ipsen Limited
  • 11. Merck & Co., Inc.
  • 12. Novartis AG
  • 13. Pfizer Inc.
  • 14. Sanofi S.A.
  • 15. Takeda Pharmaceutical Company Ltd.

LIST OF FIGURES

  • FIGURE 1. PROSTATE HEALTH MARKET RESEARCH PROCESS
  • FIGURE 2. PROSTATE HEALTH MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL PROSTATE HEALTH MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL PROSTATE HEALTH MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL PROSTATE HEALTH MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL PROSTATE HEALTH MARKET SIZE, BY DISEASE TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL PROSTATE HEALTH MARKET SIZE, BY DISEASE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL PROSTATE HEALTH MARKET SIZE, BY THERAPY TYPE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL PROSTATE HEALTH MARKET SIZE, BY THERAPY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL PROSTATE HEALTH MARKET SIZE, BY DRUG TREATMENT TYPE, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL PROSTATE HEALTH MARKET SIZE, BY DRUG TREATMENT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS PROSTATE HEALTH MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS PROSTATE HEALTH MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES PROSTATE HEALTH MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES PROSTATE HEALTH MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC PROSTATE HEALTH MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC PROSTATE HEALTH MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA PROSTATE HEALTH MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA PROSTATE HEALTH MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. PROSTATE HEALTH MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. PROSTATE HEALTH MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. PROSTATE HEALTH MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL PROSTATE HEALTH MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL PROSTATE HEALTH MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL PROSTATE HEALTH MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. PROSTATE HEALTH MARKET DYNAMICS
  • TABLE 7. GLOBAL PROSTATE HEALTH MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL PROSTATE HEALTH MARKET SIZE, BY BENIGN PROSTATIC HYPERPLASIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL PROSTATE HEALTH MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL PROSTATE HEALTH MARKET SIZE, BY PROSTATITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL PROSTATE HEALTH MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL PROSTATE HEALTH MARKET SIZE, BY AR-DIRECTED THERAPIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL PROSTATE HEALTH MARKET SIZE, BY CYTOTOXIC AGENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL PROSTATE HEALTH MARKET SIZE, BY HORMONE ADT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL PROSTATE HEALTH MARKET SIZE, BY POLY (ADP-RIBOSE) POLYMERASE (PARP) INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL PROSTATE HEALTH MARKET SIZE, BY DRUG TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL PROSTATE HEALTH MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL PROSTATE HEALTH MARKET SIZE, BY DUTASTERIDE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL PROSTATE HEALTH MARKET SIZE, BY FINASTERIDE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL PROSTATE HEALTH MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL PROSTATE HEALTH MARKET SIZE, BY ALPHA BLOCKERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL PROSTATE HEALTH MARKET SIZE, BY ALFUZOSIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL PROSTATE HEALTH MARKET SIZE, BY DOXAZOSIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL PROSTATE HEALTH MARKET SIZE, BY SILODOSIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL PROSTATE HEALTH MARKET SIZE, BY TAMSULOSIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL PROSTATE HEALTH MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS PROSTATE HEALTH MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS PROSTATE HEALTH MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS PROSTATE HEALTH MARKET SIZE, BY DRUG TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS PROSTATE HEALTH MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 31. AMERICAS PROSTATE HEALTH MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 32. AMERICAS PROSTATE HEALTH MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 33. ARGENTINA PROSTATE HEALTH MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 34. ARGENTINA PROSTATE HEALTH MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. ARGENTINA PROSTATE HEALTH MARKET SIZE, BY DRUG TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 36. ARGENTINA PROSTATE HEALTH MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 37. ARGENTINA PROSTATE HEALTH MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 38. BRAZIL PROSTATE HEALTH MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 39. BRAZIL PROSTATE HEALTH MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 40. BRAZIL PROSTATE HEALTH MARKET SIZE, BY DRUG TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 41. BRAZIL PROSTATE HEALTH MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 42. BRAZIL PROSTATE HEALTH MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 43. CANADA PROSTATE HEALTH MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. CANADA PROSTATE HEALTH MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. CANADA PROSTATE HEALTH MARKET SIZE, BY DRUG TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. CANADA PROSTATE HEALTH MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 47. CANADA PROSTATE HEALTH MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 48. MEXICO PROSTATE HEALTH MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. MEXICO PROSTATE HEALTH MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. MEXICO PROSTATE HEALTH MARKET SIZE, BY DRUG TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. MEXICO PROSTATE HEALTH MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 52. MEXICO PROSTATE HEALTH MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 53. UNITED STATES PROSTATE HEALTH MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. UNITED STATES PROSTATE HEALTH MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. UNITED STATES PROSTATE HEALTH MARKET SIZE, BY DRUG TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. UNITED STATES PROSTATE HEALTH MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 57. UNITED STATES PROSTATE HEALTH MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 58. UNITED STATES PROSTATE HEALTH MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 59. ASIA-PACIFIC PROSTATE HEALTH MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. ASIA-PACIFIC PROSTATE HEALTH MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. ASIA-PACIFIC PROSTATE HEALTH MARKET SIZE, BY DRUG TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. ASIA-PACIFIC PROSTATE HEALTH MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 63. ASIA-PACIFIC PROSTATE HEALTH MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 64. ASIA-PACIFIC PROSTATE HEALTH MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 65. AUSTRALIA PROSTATE HEALTH MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. AUSTRALIA PROSTATE HEALTH MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. AUSTRALIA PROSTATE HEALTH MARKET SIZE, BY DRUG TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. AUSTRALIA PROSTATE HEALTH MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 69. AUSTRALIA PROSTATE HEALTH MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 70. CHINA PROSTATE HEALTH MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. CHINA PROSTATE HEALTH MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. CHINA PROSTATE HEALTH MARKET SIZE, BY DRUG TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. CHINA PROSTATE HEALTH MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 74. CHINA PROSTATE HEALTH MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 75. INDIA PROSTATE HEALTH MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. INDIA PROSTATE HEALTH MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. INDIA PROSTATE HEALTH MARKET SIZE, BY DRUG TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. INDIA PROSTATE HEALTH MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 79. INDIA PROSTATE HEALTH MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 80. INDONESIA PROSTATE HEALTH MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 81. INDONESIA PROSTATE HEALTH MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. INDONESIA PROSTATE HEALTH MARKET SIZE, BY DRUG TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. INDONESIA PROSTATE HEALTH MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 84. INDONESIA PROSTATE HEALTH MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 85. JAPAN PROSTATE HEALTH MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. JAPAN PROSTATE HEALTH MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. JAPAN PROSTATE HEALTH MARKET SIZE, BY DRUG TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. JAPAN PROSTATE HEALTH MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 89. JAPAN PROSTATE HEALTH MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 90. MALAYSIA PROSTATE HEALTH MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. MALAYSIA PROSTATE HEALTH MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. MALAYSIA PROSTATE HEALTH MARKET SIZE, BY DRUG TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 93. MALAYSIA PROSTATE HEALTH MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 94. MALAYSIA PROSTATE HEALTH MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 95. PHILIPPINES PROSTATE HEALTH MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. PHILIPPINES PROSTATE HEALTH MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. PHILIPPINES PROSTATE HEALTH MARKET SIZE, BY DRUG TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. PHILIPPINES PROSTATE HEALTH MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 99. PHILIPPINES PROSTATE HEALTH MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 100. SINGAPORE PROSTATE HEALTH MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. SINGAPORE PROSTATE HEALTH MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. SINGAPORE PROSTATE HEALTH MARKET SIZE, BY DRUG TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 103. SINGAPORE PROSTATE HEALTH MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 104. SINGAPORE PROSTATE HEALTH MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 105. SOUTH KOREA PROSTATE HEALTH MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 106. SOUTH KOREA PROSTATE HEALTH MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. SOUTH KOREA PROSTATE HEALTH MARKET SIZE, BY DRUG TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 108. SOUTH KOREA PROSTATE HEALTH MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 109. SOUTH KOREA PROSTATE HEALTH MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 110. TAIWAN PROSTATE HEALTH MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 111. TAIWAN PROSTATE HEALTH MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 112. TAIWAN PROSTATE HEALTH MARKET SIZE, BY DRUG TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. TAIWAN PROSTATE HEALTH MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 114. TAIWAN PROSTATE HEALTH MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 115. THAILAND PROSTATE HEALTH MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. THAILAND PROSTATE HEALTH MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 117. THAILAND PROSTATE HEALTH MARKET SIZE, BY DRUG TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. THAILAND PROSTATE HEALTH MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 119. THAILAND PROSTATE HEALTH MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 120. VIETNAM PROSTATE HEALTH MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 121. VIETNAM PROSTATE HEALTH MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. VIETNAM PROSTATE HEALTH MARKET SIZE, BY DRUG TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 123. VIETNAM PROSTATE HEALTH MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 124. VIETNAM PROSTATE HEALTH MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 125. EUROPE, MIDDLE EAST & AFRICA PROSTATE HEALTH MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 126. EUROPE, MIDDLE EAST & AFRICA PROSTATE HEALTH MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA PROSTATE HEALTH MARKET SIZE, BY DRUG TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA PROSTATE HEALTH MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA PROSTATE HEALTH MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA PROSTATE HEALTH MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 131. DENMARK PROSTATE HEALTH MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 132. DENMARK PROSTATE HEALTH MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 133. DENMARK PROSTATE HEALTH MARKET SIZE, BY DRUG TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. DENMARK PROSTATE HEALTH MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 135. DENMARK PROSTATE HEALTH MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 136. EGYPT PROSTATE HEALTH MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. EGYPT PROSTATE HEALTH MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 138. EGYPT PROSTATE HEALTH MARKET SIZE, BY DRUG TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. EGYPT PROSTATE HEALTH MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 140. EGYPT PROSTATE HEALTH MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 141. FINLAND PROSTATE HEALTH MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. FINLAND PROSTATE HEALTH MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. FINLAND PROSTATE HEALTH MARKET SIZE, BY DRUG TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 144. FINLAND PROSTATE HEALTH MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 145. FINLAND PROSTATE HEALTH MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 146. FRANCE PROSTATE HEALTH MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 147. FRANCE PROSTATE HEALTH MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 148. FRANCE PROSTATE HEALTH MARKET SIZE, BY DRUG TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 149. FRANCE PROSTATE HEALTH MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 150. FRANCE PROSTATE HEALTH MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 151. GERMANY PROSTATE HEALTH MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 152. GERMANY PROSTATE HEALTH MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 153. GERMANY PROSTATE HEALTH MARKET SIZE, BY DRUG TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 154. GERMANY PROSTATE HEALTH MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 155. GERMANY PROSTATE HEALTH MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 156. ISRAEL PROSTATE HEALTH MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 157. ISRAEL PROSTATE HEALTH MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 158. ISRAEL PROSTATE HEALTH MARKET SIZE, BY DRUG TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 159. ISRAEL PROSTATE HEALTH MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 160. ISRAEL PROSTATE HEALTH MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 161. ITALY PROSTATE HEALTH MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 162. ITALY PROSTATE HEALTH MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 163. ITALY PROSTATE HEALTH MARKET SIZE, BY DRUG TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 164. ITALY PROSTATE HEALTH MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 165. ITALY PROSTATE HEALTH MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 166. NETHERLANDS PROSTATE HEALTH MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 167. NETHERLANDS PROSTATE HEALTH MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 168. NETHERLANDS PROSTATE HEALTH MARKET SIZE, BY DRUG TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 169. NETHERLANDS PROSTATE HEALTH MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 170. NETHERLANDS PROSTATE HEALTH MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 171. NIGERIA PROSTATE HEALTH MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 172. NIGERIA PROSTATE HEALTH MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 173. NIGERIA PROSTATE HEALTH MARKET SIZE, BY DRUG TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 174. NIGERIA PROSTATE HEALTH MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 175. NIGERIA PROSTATE HEALTH MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 176. NORWAY PROSTATE HEALTH MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 177. NORWAY PROSTATE HEALTH MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 178. NORWAY PROSTATE HEALTH MARKET SIZE, BY DRUG TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 179. NORWAY PROSTATE HEALTH MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 180. NORWAY PROSTATE HEALTH MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 181. POLAND PROSTATE HEALTH MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 182. POLAND PROSTATE HEALTH MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 183. POLAND PROSTATE HEALTH MARKET SIZE, BY DRUG TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 184. POLAND PROSTATE HEALTH MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 185. POLAND PROSTATE HEALTH MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 186. QATAR PROSTATE HEALTH MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 187. QATAR PROSTATE HEALTH MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 188. QATAR PROSTATE HEALTH MARKET SIZE, BY DRUG TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 189. QATAR PROSTATE HEALTH MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 190. QATAR PROSTATE HEALTH MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 191. RUSSIA PROSTATE HEALTH MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 192. RUSSIA PROSTATE HEALTH MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 193. RUSSIA PROSTATE HEALTH MARKET SIZE, BY DRUG TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 194. RUSSIA PROSTATE HEALTH MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 195. RUSSIA PROSTATE HEALTH MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 196. SAUDI ARABIA PROSTATE HEALTH MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 197. SAUDI ARABIA PROSTATE HEALTH MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 198. SAUDI ARABIA PROSTATE HEALTH MARKET SIZE, BY DRUG TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 199. SAUDI ARABIA PROSTATE HEALTH MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 200. SAUDI ARABIA PROSTATE HEALTH MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 201. SOUTH AFRICA PROSTATE HEALTH MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 202. SOUTH AFRICA PROSTATE HEALTH MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 203. SOUTH AFRICA PROSTATE HEALTH MARKET SIZE, BY DRUG TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 204. SOUTH AFRICA PROSTATE HEALTH MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 205. SOUTH AFRICA PROSTATE HEALTH MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 206. SPAIN PROSTATE HEALTH MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 207. SPAIN PROSTATE HEALTH MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 208. SPAIN PROSTATE HEALTH MARKET SIZE, BY DRUG TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 209. SPAIN PROSTATE HEALTH MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 210. SPAIN PROSTATE HEALTH MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 211. SWEDEN PROSTATE HEALTH MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 212. SWEDEN PROSTATE HEALTH MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 213. SWEDEN PROSTATE HEALTH MARKET SIZE, BY DRUG TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 214. SWEDEN PROSTATE HEALTH MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 215. SWEDEN PROSTATE HEALTH MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 216. SWITZERLAND PROSTATE HEALTH MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 217. SWITZERLAND PROSTATE HEALTH MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 218. SWITZERLAND PROSTATE HEALTH MARKET SIZE, BY DRUG TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 219. SWITZERLAND PROSTATE HEALTH MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 220. SWITZERLAND PROSTATE HEALTH MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 221. TURKEY PROSTATE HEALTH MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 222. TURKEY PROSTATE HEALTH MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 223. TURKEY PROSTATE HEALTH MARKET SIZE, BY DRUG TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 224. TURKEY PROSTATE HEALTH MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 225. TURKEY PROSTATE HEALTH MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 226. UNITED ARAB EMIRATES PROSTATE HEALTH MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 227. UNITED ARAB EMIRATES PROSTATE HEALTH MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 228. UNITED ARAB EMIRATES PROSTATE HEALTH MARKET SIZE, BY DRUG TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 229. UNITED ARAB EMIRATES PROSTATE HEALTH MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 230. UNITED ARAB EMIRATES PROSTATE HEALTH MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 231. UNITED KINGDOM PROSTATE HEALTH MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 232. UNITED KINGDOM PROSTATE HEALTH MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 233. UNITED KINGDOM PROSTATE HEALTH MARKET SIZE, BY DRUG TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 234. UNITED KINGDOM PROSTATE HEALTH MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 235. UNITED KINGDOM PROSTATE HEALTH MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
  • TABLE 236. PROSTATE HEALTH MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 237. PROSTATE HEALTH MARKET, FPNV POSITIONING MATRIX, 2023